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Abstract 
At the beginning of 2020, the World health organization (WHO) declared 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as 
responsible for the coronavirus disease 2019 (COVID-19) outbreak. Previous 
studies showed that microRNAs (miRNAs) can inhibit the pathogenesis of 
DNA or RNA viruses by binding the genome. The purpose of the current study 
was an overview of the anti-viral role of cellular miRNAs against COVID-19 
infection. Our search was limited to all published original papers in the English 
language from 2019 to 2021 using several databases including PubMed, 
Google Scholar, Scopus, and Science Direct. A manual search of references for 
included articles was also performed. Among 66 electronically searched 
citations, 17 papers met the inclusion criteria. The presence of miRNAs during 
the COVID-19 infection, reported by several studies, predicts the possibility of 
using miRNAs as potential tools to eradicate the SARS-CoV-2 infection. In 
some studies, miRNAs have presented as a tool for targeting SARS-CoV-2 
encoded genes which are essential in viral biogenesis, entrance, replication, 
and infection. The comparison of miRNA between SARS-CoV-2 with other 
human coronaviruses will help the better understanding of distinct clinical 
characteristics. 
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Introduction 
Highly pathogenic zoonotic coronaviruses have been 
reported over the past two decades, including severe 
acute respiratory syndrome-Coronavirus (SARS-
CoV), and the Middle East respiratory syndrome 
coronavirus (MERS-CoV) in 2002/2003 and 2012. 
Recently, the outbreak of Coronavirus Disease 2019 
(COVID-19) was caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and 
distributed worldwide (1). Patients with underlying 
diseases like Acute Respiratory Distress Syndrome 
(ARDS), Diabetes mellitus, cardiovascular diseases, 
hepatitis, enteric diseases, and central nervous diseases 
have a greater risk of mortality when infected with 
COVID-19 (2).  
SARS-CoV-2 belongs to β CoV and is a 
positive-single-stranded RNA (+ssRNA) virus with a 
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genome size of 30kb. In addition to non-structural 
proteins, SARS-CoV-2 encodes structural proteins like 
the spike protein (S), an envelope protein (E), 
membrane protein (M), the nucleocapsid protein (N) as 
well (3).  
SARS-CoV-2 is more contagious than SARS-
CoV (4) while sequence base analysis illustrates 
almost 79% similarity among them. Two unforeseen 
O-glycosylation sites on the receptor-binding domain 
(RBD) of the virus probably increase the pathogenicity 
of COVID-19 during infection (5). The S1 subunit of 
S protein that contains RBD binds to the angiotensin-
converting enzyme 2 (ACE2) on alveolar epithelial 
cells, using TMPRSS2 as a cellular protease for 
priming of SARS-COV-2 S glycoprotein when the S2 
subunit facilitates the fusion and entrance process. 
Actually, ACE2 and TMPRSS2 have the critical roles 
during host cell entry phase of virus (5, 6).  
The main strategies for preventing the SARS-
CoV-2 infection are inhibiting the viral replication 
viral proteins synthesis and obstruction of virus entry 
(7). On the other hand, experimental pieces of evidence 
showed that some host-encoded MicroRNAs 
(miRNAs) can facilitate an intracellular defense tool 
against some RNA viruses (8). Therefore, miRNAs can 
repress the viral transcription or translation via binding 
to the 3′ untranslated region (3′UTR) of the viral 
messenger RNA (mRNA). In fact, after the formation 
of an RNA-induced silencing complex (RISC), 
miRNA can bind to 3′-UTR and the coding region of a 
target gene to induce translation repression or mRNA 
degradation. MiRNAs are non-coding and short RNAs 
that negatively regulate gene expression and involve in 
various pathologies such as cancer, apoptosis, and 
metabolism (8).  
The levels of many pro-inflammatory effector 
cytokines, such as TNF, IL-1β, IL-6, IL-8, G-CSF, and 
GM-CSF, as well as chemokines, such as MCP1, IP10, 
and MIP1α, are elevated in SARS-CoV-2 infection. On 
the other hand, miRNAs can decrease the levels of 
these immunomodulatory factors as a molecular brake 
to modulate inflammation (3). Hence, the development 
of a miRNAs-based vaccine is highly useful to inhibit 
COVID-19 infection.  
Researchers struggle to develop an effective 
SARS-CoV-2 vaccine to control and eradicate SARS-
CoV-2 infections. Therefore, understanding the 
behavior of miRNAs may create new opportunities for 
the development of the miRNA-based anti-viral for 
SARS-CoV-2 infection. This systematic review 
attempts to help interested researchers for choosing the 
potent strategy to control COVID-19 by collecting the 
data on bioinformatic identification of miRNA-based 





Literature search: This systematic research was 
conducted for the over the research studies published 
on bioinformatics identification of microRNA 
mediated interactions in COVID-19 infection from 
2019 to September 2020 using several national and 
international databases including; Pubmed, Google 
Scholar, Scopus, and Science Direct (fig. 1). The 
research was limited to the original articles published 
in English. The following keywords were used from 
medical subject headings: titles or abstracts “Severe 
Acute Respiratory Syndrome- Coronaviruses-2” OR 
“SARS-COV-2” OR “2019 Novel Coronavirus” OR 
“Novel Coronaviruses” AND “miRNA” OR 
“microRNA” OR “Non-Coding RNA”. The search was 
performed by 2 independent researchers.  
 
Study selection: All the articles including the full text, 
abstract, pieces of evidence, and reports were provided 
for the current systematic review. We first exclude all 
duplicates. Then, irrelevant papers were deleted after 
reviewing titles, abstracts, and full texts. Generally, we 
reviewed articles that introduced miRNAs that were 
attached to structural and non-structural proteins. 
Finally, 17 papers were used for our study (Fig. 1).  
 
Data extraction: The data were extracted from 17 
selected articles, including the first author, country, 
year of publication, Human miRNA, viral target gene, 




In the current review study, 66 articles were identified 
through the initial searches, among them, 17 articles 
met the inclusion criteria and 14 articles were excluded 
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because of being review articles, letters to editors, or 
having irrelevant titles. Table 1 presents a summary of 
the involved cellular miRNAs  
Table 1: Vasoactive inotrope score in various groups. 




















3'UTR, 5'UTR - 
[11] Liu  
(China, 2020) 
miR-4661-3p S region 
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let-7e,  mir-125a, mir-141,  
miR-200 
- ACE2 / TMPRSS2 
[14] Lu 
(Germany, 2020) 
miR-200c-3p - Ace2 mRNA and Ace2 protein 
[15] Haddad 
(Amman, 2020) 
hsa-miR-3620-3p S region - 
[16] Teodori 
(Italy, 2020) 





5p, miR-3065-5p and miR-
421 
- These miRNAs can regulate all 
human coronaviruses via direct 
binding to viral RNAs. 
[7] Balmeh  
(Iran, 2020) 
miR-1307-3p 3′UTR 1.TGF- and semaphorin 
signaling 
2.PI3K/Act signaling pathway 
3.endocytosis signaling pathway 
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[19] Arisan 
(the UK, 2020) 
miR-8066 N region 1.Activation of NfKB-mediated 
TLR-8 expression 
2.Activation of the cytokine 
storm 
3. Alteration of  N-glycosylation 
patterns 
miR-3934-3p - 1.glycosaminoglycan 
biosynthesis heparan sulfate 
(Heparan sulfate proteoglycans 
can provide the binding sites for 
SARS-CoV-2 ) 
 2.Vitamin digestion and 
absorption (vitamin D and B3 
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miR-190a-5p ORF6 - 
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miR-6762-3p, miR-6746-





miR-129-5p S region ORF10  - 
[22] Chow  
(Canada, 2020) 
miR-5047 M  - 
miR-1301-3p N - 










mir-27b-3p - ACE2 




The pandemic of SARS-CoV-2 is a serious public 
health crisis that raised plenty of global concerns. 
Access to appropriate therapeutics can confine the 
COVID-19 disease in human communities.  
The presence of miRNAs during the COVID-19 
infection, reported by several studies (table 1), predicts 
the possibility of using viral or cellular miRNAs as 
potential tools to eradicate the SARS-CoV-2 infection. 
Indeed, in some studies, miRNAs have presented as a 
tool for targeting SARS-CoV-2 encoded genes which 
are essential in viral biogenesis, entrance, replication, 
and infection (Table 1). 
 
 
Figure 1. Flowchart of the search strategy. 
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Khan et al. reported that SARS-CoV-2 can 
encode miRNAs that can target the broad immune 
signaling pathways such as the insulin signaling 
pathway and complicate the condition of COVID-19 
patients with underlying diabetic problems. Also, some 
SARS-CoV-2 miRNAs can target autophagy and IFN-
I signaling that resulted to prolong the latent phase 
without any symptoms of COVID-19 and also 
increasing anomalies in underlying patients. In another 
study, Liu et al. reported that SARS-CoV-2 produces a 
miRNA (MR147-3p) which increases the infection due 
to the overexpression of TMPRSS2 that cleaves the S 
glycoprotein. Furthermore, some cellular miRNAs can 
regulate the ACE2 and TMPRSS2 expression that have 
an enzymatic role and are essential for cell entrance of 
virus during COVID-19 infection.  
Moreover, some cellular miRNAs such as miR-
8066 act as a double-edged sword in COVID-19 
disease. MiR-8066 can target the RBD of subunit S1 to 
block the attachment of SARS-CoV-2 to ACE2, and 
also it is associated with the cytokine storm in SARS-
CoV-2 infection. On the other hand, several studies 
have shown that miRNA expression decreases in aged 
patients with underlying conditions resulted in better 
replication of the SARS-CoV-2 genome and more viral 
particle production in comparison to younger people. 
In fact, in young individuals, miRNAs bind to viral 
genomes more successfully and prevent the 
accumulation of viral particles (9). 
There is an antiviral role for cellular miRNAs 
when some viruses can manipulate and degrade 
cellular miRNAs to inhibit their maturation for their 
advantage (8). Therefore, investigation on the potential 
roles of miRNA in host-virus interaction is essential to 
design an appropriate vaccine for COVID-19.  
Moreover, some of the blood-based biomarkers 
such as miR-146a-5p that have been found in the 
patients infected by COVID-19 can suggest a 
molecular link between SARS-CoV-2 infection and 
inflammation, therefore these findings open a new 
window in understanding SARS-CoV-2 pathogenesis 
to cure COVID-19 infection. 
In reviewed articles here, a lot of miRNAs are 
introduced, their interactions with the SARS-CoV-2 
genome should be examined via further in-vivo and in-
vitro studies to validate the potential therapeutic 
targets. Studies on the side effects of these miRNAs in 
humans are needed when further research is required 
on plenty of patient-derived samples. Furthermore, the 
comparison of miRNA between SARS-CoV-2 with 
other human coronaviruses will help the better 
understanding of distinct clinical characteristics.  
 
Conclusion    
The comparison of miRNA between SARS-CoV-2 
with other human coronaviruses will improve our 
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